Molecule to Market: Inside the outsourcing space (Raman Sehgal)

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Founder and CEO at Vibe Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alok, covering:

• The personal story that motivated and inspired Alok to create a rare disease platform focused entirely on creating an ecosystem focused on high potential medicines.
• Lessons from ‘the grind’ of raising over $100m in capital, and why you need a ‘Minimal Viable Investor’ (MVI)
• The macro impact of Covid-19 in highlighting the importance of medicines - and why this is a time for optimism, innovation and technology in biotech.
• The catch-22 of inflection points for biotechs and how that impacts access to capital. And whether AI could play a pivotal role.
• How CDMOs and CROs need to evolve away from just the fee-for-service model to explore longer-term, partnership-led alternatives.

Alok has 15 years of experience as a scientist and 12 as a serial entrepreneur. After completing postdoctoral work at Harvard University with George Whitesides, Alok started two pharma SaaS companies, PreScouter and TetraScience, which employ several hundred people combined and have more than four hundred customers. He also launched and led the life sciences division of Egnyte, a cloud content governance company based in California, and grew the business to a 60-person team and eight-figure run rate.

Alok founded Vibe Bio after his daughter was hospitalized at birth and he learned first-hand that the biggest obstacle to developing treatments isn’t finding potential therapies — it’s funding them. Vibe Bio is helping patients in similar situations overcome that obstacle by scaling the development of treatments for rare disorders sustainably for the first time. He holds a B.S. from Cornell and a Ph.D. from Northwestern, both in Materials Science & Engineering.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Harry Christiaens, CEO at Ardena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Harry, covering:

• How a regulatory change led a small consultancy down the path of becoming one of Europe’s most respected mid-sized CDMOs
• The easy-theory of an M&A buy-and-build strategy, versus the challenging practical realities after acquiring and integrating five businesses
• Key considerations and questions you should ask before selecting a private equity partner
• The role of nano-technology in producing nanomedicines for effective targeting of disease…but also the challenges of dealing with this enabling platform
• Why there is cause for optimization for CDMOs when looking at the robust R&D funding environment and forecasted outsourcing growth

Harry has significant leadership experience with 20+ years in the pharma and biotech industry. He successfully transformed Pharmavize, a regulatory consultancy company into a leading CDMO, establishing a GMP team and infrastructure from scratch. Since 2015, he led the acquisitions and integration of five companies providing highly complementary services. He successfully integrated the service offering of the acquired companies onto one platform, creating the Ardena brand.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Bittorf, Founder and Principal Consultant of SCxCMC.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:

• Joining a little company called Vertex Pharma when it was looking to be innovative
• The leap of faith required to become a consultant, and why helping smaller businesses makes a bigger difference
• An insight into the sentiment of virtual, small, and emerging biotechs after a brutal 12 months
• What the most significant factor is in CDMO selection for biotechs, as well as other critical components
• Why CMC is a crucial investment from pre-IND to phase 2 to get things done on time

Kevin is an experienced consultant who has demonstrated success in pharmaceutical development (innovator and generics) and technical innovation. Leveraging his extensive experience in GMP, business development, contract manufacturing, and long-term strategy, Kevin partners with biopharma CEOs and executives to guide their companies through groundbreaking pharmaceutical advancements by evaluating strategy, attaining government approvals, and developing new and emerging technologies that improve the development lifecycle.

He has formed multiple non-profit conferences, including the Advancing Drug Development Forum, which examines how innovations are brought from inception to regulatory approval. He has spent time at Vertex and Trek Therapeutics and advising several CDMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special roundtable episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

Jean-Jacques Mondoloni, Managing Partner WOMBAT CAPITAL

Mark Quick, Executive Vice President Corporate Development at Recipharm

Gerry Cox, Vice President at Pace Life Sciences

Your host, Raman Sehgal, discusses M&A trends in the pharmaceutical and biotechnology supply chain, covering:

• What a real-life M&A deal in outsourcing looks like from the buyer, seller and advisor angle.
• How the dynamics of M&A have changed over the last decade given the fragmented marketplace alongside increased funding, PE-interest and a pandemic spotlight now on the sector.
• Dizzying multiples, the fight for assets and key factors driving deals and valuations in contract services.
• Predictions from the panel around the future of deal flow in the outsourcing space... will the current velocity continue?

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adrienne Leussa, Director of Ecosystem Partnerships at 54gene.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adrienne, covering:

• How the reality of the health challenges living in Africa as a child drove Adrienne into the drug discovery space.
• A rich insight into the only remaining high growth market globally for pharma companies.
• Learn about the main cities driving drug development growth within Africa and the prospect for more localised manufacturing.
• Life working for one of the leading biotech companies in Africa.
• Living life by curiosity as an ethos to make a lasting impact in the world.

Adrienne is a Biochemist (PhD) with 10+ years of hands-on experience and a plethora of diverse technical skills within the area of drug discovery and development. She has also worked as a lecturer and researcher in top African universities helping inspire a generation of scientists through access to information on the applications of biotechnology.She is fluent in 3 of the most used languages in Africa: Portuguese, French and English, and is ardent about continued learning, cross-culture collaboration, problem solving, customer service and mentoring.Adrienne’s mission is to elevate Africa through high quality, innovative, and credible scientific output for global prosperity.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Lee Ph.D., President at the CDMO Division of Lubrizol Life Science Health (LLS). Rob has over 30 years’ experience in the pharmaceutical R&D space and his areas of expertise include drug delivery, formulation development, analytical sciences and sterile manufacturing. With a Ph.D. in Physical Bioorganic Chemistry, Rob has published more than three dozen articles and five book chapters. Plus, he holds 11 issued patents and 15 provisional or PCT patent applications. He has worked for some major companies in the sector and was appointed President of the CDMO Division of LLS after 10 years with the business.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob Lee, covering the new paradigm for drug development and manufacturing after the speed to market achieved by the COVID-19 vaccines. Rob then explains how patient-friendly dosage forms will continue to play an increasingly important role in the future. Rob also gives us an idea of the types of molecules and projects coming through the pipeline at the moment and what is in store for LLS. Lastly Rob shares what it’s been like to transition from a scientist to a leader while keeping science at the heart of everything he does. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mihaela Simianu, Vice President of R&D and Operations at Singota Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mihaela, covering:

• How having physician parents in Romania motivated Mihaela into a career in the biopharmaceutical space
• What 17 years at Eli Lilly taught her about drug development and commercialization... and why she ultimately left for Amgen
• Why, after 25 years on the drug sponsor-side, she opted to move onto the CDMO side
• The rapid, complex, and fascinating experience of being part of a small CDMO that supports multiple sponsors to serve patients
• The advisory and execution role of a CDMO partner

Dr. Simianu is a transformational leader in the biopharmaceutical industry, renowned for advancing technology and therapeutic products to enhance personalized medicine and public health. She has achieved significant outcomes for multi-billion-dollar organizations, leading to the approval of 20+ new therapeutic agents and the introduction of commercial processes at more than thirty manufacturing sites globally across her tenure with Eli Lilly, Amgen, and Merck.

Her expertise spans multiple disease areas, and she excels in integrating raw material suppliers, facilities, and engineering equipment into pharmaceutical systems. Specializing in modern product development, quality, and manufacturing systems, she has played a pivotal role in injectable drug commercialization and market expansion. She advanced a portfolio of over thirty-five new pipeline products.

Dr. Simianu holds a Ph.D. in Chemistry from Marquette University, an M.S./B.S. in Chemical Engineering from the Babes-Bolyai University of Cluj-Napoca, and a Jack Welch Management Institute certification. She is a recognized international industry expert and has actively volunteered for the Parenteral Drug Association for over 20 years.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bobby Sheng, CEO and Chairman of Bora Pharmaceuticals.  A California native and an experienced leader in the pharmaceutical industry, Bobby is skilled in international business, management, mergers & acquisitions, finance, and marketing. He graduated from University of California, Berkeley and now resides in Taiwan.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Bobby Sheng, speaking on Bobby’s time as a producer in the film industry and the lessons he gained from producing nine films. Bobby explains his key focus areas as a leader and how he tries to keep them top of mind as he progresses through his career. He also explains the importance of having the right people on your team and describes them as the best and strongest asset an organization can have. Lastly, Bobby speaks on the pharma production industry. He believes there is room to adopt efficiencies and technologies in order to move away from the archaic batch production system.  

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason Lacombe, CEO at Veratrak. A graduate of Toronto and Oxford University, Jason was recently named as one of Forbes 30 Under 30 and has also advised the WHO and EU. Today, his business is one of the fastest growing tech companies in the life science space.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering the impact Covid-19 has had on accelerating the digitisation of the global pharmaceutical supply chain. Jason speaks about dealing with inertia and how it is now more clear than ever; the old way of doing things is not fit for our modern world. Lastly, Jason touches on the importance of aiming for less stock outs, faster leader times, more secure documentation and most importantly, better patient outcomes. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with John Fowler, President & CEO at Pii (Pharmaceutics International, Inc.)

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with John, covering:

• How a competitive family environment and navigating flight school in the Navy equipped him for a successful career
• Why a CDMO business is like managing chaos... under strict regulations
• The silver lining of the pandemic - quality time with his family
• Why he decided to leave Johnson Matthey after 30 years and take a 'title' step back
• Bringing PII back to its former glory and rebuilding a management team

John Fowler brings more than 30 years of pharmaceutical and chemical industry experience to Pii. He most recently served as President and Chief Operating Officer of Piramal Pharma Solutions, a CDMO serving generic companies worldwide. Before joining Piramal, he was the Divisional CEO of the Global Fine Chemical business at Johnson Matthey.

Mr. Fowler also held senior leadership roles in several business verticals at JM, including Pharmaceutical Materials and Services, Environmental Catalysts, and Technologies. He has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Garabedian, CEO at Xontogeny and Venture Fund Manager at Perceptive Advisors.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:

• How he utilized his pharma experience to become a CEO and revitalize a biotech company, positioning it for a $15bn market cap
• Why the biotech space had such a market downturn, and how the uptake in the industry will be data-driven
• Demystifying the role of a biotech CEO and understanding what it takes to drive successful drug development
• Why relying on outsourcing is critical for biotechs today
• The emerging, secondary-tier biotech clusters in the US... but why does Boston remain unrivalled?

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which supports early-stage companies with Series A investments across biotech, medtech and healthtech.

Chris has a broad base of experience and a track record of success over his decades-long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space. He also led Corporate Strategy for Celgene from 2007 to 2010 and served in several global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

He serves on the boards of several life sciences companies and speaks at industry conferences on a wide range of important issues. He is a member of the Corporate Relations Board for the Keck Graduate Institute. He has previously served on the Board of Directors of MassBio and is a Senior Advisor for the Boston Consulting Group.

-----

Join Molecule to Market and ramarketing for an exclusive panel discussion series at this year's CPHI Milan - across 3 power-packed sessions, our industry experts will be sharing insights into driving brand growth with strategic marketing.

Find out more and pre-register here

-----

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA). Previous to launching PBOA in 2014, Gil helped launch Contract Pharma in 1999 and served as the founding editor for 15 years. Contract Pharma has since grown to become one of the most respected magazines in the industry.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Gil Roth, speaking on the tremendous impact the PBOA has made with congress and the FDA on behalf of the contract manufacturing industry. Gil offers some insight on how the PBOA has found success in influencing representatives and senators in Washington to learn about the sector and advocate on its behalf. Gil reflects on the ways the industry has changed over the past couple of decades, such as the sophistication of acquisitions and the willingness to openly outsource from a reputation standpoint. Raman and Gil identify the trends and challenges they have noticed in a time where once common business practices have been stripped away as we all adapt to this new normal. Lastly Gil speaks about his own podcast, The Virtual Memories Show, and the impact and joy it has created over the years. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Bamforth, Entrepreneur, Mentor and Investor in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:

• How an unsolicited offer led to the unplanned sale of Arranta Bio to global CDMO Recipharm
• Mark’s ability to spot trends of where the sector is going, and sometimes going against conventional wisdom
• How Mark thinks about investment in early stage and later stage companies, as an investor
• His take on the tougher, tighter funding environment and what it means for the market
• Leadership lesson from 20+ years at Genzyme and three founder-to-exit successes

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lung-I, covering:

• His take on the different models of healthcare he has seen globally, and the value they do and don’t deliver to patients
• The access, and infrastructural challenges of CGT products and ways to bring the cost of goods down
• Why CGT is the therapy of the future... but why we must remember it’s not the only modality out there
• What the future looks like for CGT and exploring what happens when we have a treatment that can treat a lot more patients

Lung-I Cheng, Ph.D., is Vice President, Cell and Gene Therapy, leading AmerisourceBergen’s Cell and Gene Therapy (CGT) service line. In his role, he advances AmerisourceBergen’s CGT strategy with a focus on expanding the company’s portfolio of services to better support CGT innovators throughout the commercialization journey.

Before joining AmerisourceBergen, he spent a decade in biopharma, most recently serving as the head of Global Value & Access for Cell Therapies, Pipeline, and Business Development at Takeda.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Barbara Morgan, Global Vice-President of Pharma and Biotechnology at Kerry.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Barbara, covering:

• Believing in herself and being brave enough to leave a company that felt like family in a job that she loved
• Why Pharma has proved itself to be indispensable, while the biopharma slowdown is just a blip
• The difference between mentors and sponsors, and why you need a blend of both
• Lessons for mastering M&A assessment and integration for prioritizing impact

Barbara Morgan is Global Vice-President, Pharma, and Biotechnology at Kerry. Prior to that she worked at LLS Health (part of Lubrizol) from 2014 until 2021 and was named General Manager in 2018.

With a Ph.D. in Organic Chemistry from the University of Pennsylvania (US), Dr Morgan has more than 15 years of experience in the Life Science industry, covering pharmaceutical, nutraceutical, and medical devices.  She has published numerous articles in peer-reviewed journals and holds patents, including one on the treatment of cancer stem cells.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ata Tuna Ciftlik CEO at Lunaphore.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ata, covering:

• Bringing the next generation ‘satellite for tumours’ sequencing tools for immuno oncology and cancer research to drug discovery, and eventually the mainstream.
• Why life science start-ups need data to survive and thrive. And key lessons of entrepreneurship, from theory to reality.
• The avalanche effect - from a 2.5k competition fundraise to $50m in a market on-track to become $10b.
• Unmissable leadership lessons from PhD-start up to global life science business.

Ata Tuna Ciftlik was born in Ankara, Turkey. He received a double-B.Sc in Mathematics and Electronics Engineering from Middle East Technical University (METU) in 2006. He started interdisciplinary research at the interface of Microfluidics and Biology during his MSc studies in METU, where he received thesis of the year 2009 prize.

Next, he obtained interdisciplinary PhD in Biomedical Microfluidic Systems from Swiss Institute of Technology in Lausanne (EPFL) and was awarded internationally known Dimitris N. Chorafas foundation prize in the category of cutting egde technology.After inventing its core technology during his PhD, he has co-founded Lunaphore in 2014.

Lunaphore so far received USD 60 million financing from private and public sources, lead multiple innovation projects in Switzerland and Europe, counts close to 100 people, appeared more than 100 times in national and international media channels, claimed 22 awards and has consistently been selected as one of the best start-ups in the country. Ata Tuna is married, has 2 children and enjoys biking, running and hiking.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Vice President of Life Sciences at Egnyte and the founder of the Biotech 2050 podcast. Alok has a very impressive academic and entrepreneurial background in life sciences, before running the fast-growing life science division at Egnyte, he was a Co-Founder of PreScouter and TetraScience, raising millions along the way. Having completed a postdoctoral fellowship at Harvard University, he has also been published in Forbes and Nature.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole loaf more) with Alok, covering how he founded, built and scaled two life science software companies… and then did it all over again as a vertical of a larger organisation. Alok shares the lessons he learned while raising millions in VC capital and the value of building relationships early on. He explains how CDMOs and CROs can become more strategic with biotech clients by seeing themselves as data and knowhow specialists. Finally, Raman and Alok discuss the journey of the contract services space and how the landscape has shifted from a largely transactional rigid business to becoming the foundational bedrock of the life science domain. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ben Locwin, Chief Scientist, Head of Clinical Services and Project Sciences at Black Diamond Networks (BDN).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ben, covering:

• Being part of the Lonza growth story in its 'scrappy' years
• Learning never to say no to a good opportunity and how that's opened many doors
• Becoming part of the more significant patient conversations at Biogen
• Dropping in seal teams to help companies do what they may never have achieved
• Why is change always inevitable in our sector, and what may the future hold for us all?

As the saying goes, we're all a product of our growth and past experiences. Ben Locwin is an industry and healthcare executive who has been variously described as a "Remarkably talented speaker" by the Association for Talent Development, a "Rockstar epidemiologist" by NPR, a "healthcare futurist" by Contract Pharma and Rodman Media, and "a good friend" by ...his friends.

He began his journey as an astrophysicist 30 years ago and then transitioned into the world of biotech in the 1990s when the nascent industry was yet poised to take over the world. He has specialized training as a neuroscientist and has worked with some of the top companies in the industry, both as a leader and a consultant.

He has been a member of several Boards, association committees, steering teams, Task Forces, and scientific advisory panels.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Last week marked the return of DCAT in New York City. A prestigious event that’s open to companies engaged in the Biotech and Pharmaceutical manufacturing space…

With the massive return this year of events. Your host, Raman Sehgal, decided to shake things up this year and do things differently, taking your favourite life science podcast Molecule to market with him… Equipped with only a laptop and a microphone, he hit the event space in style and interviewed some great guests along the way.

Listen to a variety of select guests at the top of their field. 

• Yasmin Davoodi, Head Of Commercial at ramarketing

• Jon Lenihan, Head of Sales & Business Development, CDMO Business Unit Head at Emergent Biosolutions

• David Enloe, President and CEO of Societal™ CDMO (formerly Recro)

• Gil Roth, President, Pharma and Biopharma Outsourcing Association

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marco Chiado’ Piat, President, at Terumo Pharmaceutical Solutions part of Terumo. Marco has worked in the pharma and healthcare sector since the early 1990s. His impressive experience has included eight years at McKinsey before he founded a VC business. He then had several senior roles at medical device specialist LivaNova before joining Terumo Pharmaceutical Solutions in 2017, where he has risen to the top. If that was not enough, he’s an accomplished marathon runner and runs a winery in Northern Italy with his brother.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Marco Chiado’ Piat covering the importance of passion, curiosity and simply liking what you do as important pillars for serving your purpose. Marco explains how running marathons and ultra marathons has not only helped train his body for resistance but has also trained his mind for resilience. He tells Raman of the unrest Covid has caused medical device companies, and the apparent value of long term thinking that is inherent in the pharmaceutical sector. Marco closes with the importance of being ready for the unknown and unforeseen by having an ‘agility muscle’ ready to flex into action.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with independent life sciences consultant Jim Miller. Your host, Raman Sehgal sits down with Jim covering:

• The three biggest macro factors impacting the CDMO space right now
• How CDMOs and CROs are starting to feel the pain of emerging biotech’s funding woes
• What we can learn from the 08-09 financial crash that can help CDMOs/CROs during rockier financial times
• The cooling of M&A and company valuations, and why financial stability may become a more important selection criteria
• Where Jim would place his attention and money if he was running a CDMO...

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason McKenna, Global President, and Dean McAlister, Executive Vice President both from Inizio Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with the dynamic duo, covering:

• A wealth of big pharma learnings for today’s emerging biotechs.
• The (good and bad) impact of the current biotech capital market slowdown on decision-making for outsourced service providers.
• What the future may look like in our space in terms of financing and therapeutic impact.
• Learnings from how to make a business relationship successes from complementary colleagues.

Jason spent the initial part of his career in big pharma, working for AstraZeneca in the US and UK across a variety of marketing, sales and finance roles. He is now the Global President of Inizio’s first enterprise business unit, Inizio Biotech. Jason and his team enable biotech partners to maximize the value of their assets by providing scalable support, through the seamless experience of a single point of coordination. Previously CEO at STEM, an Inizio Advisory company, Jason led the organization through significant scaling and transformation throughout the COVID pandemic.

Dean has over 35 years of biopharma experience across established and startup organizations – including 28 years with AstraZeneca in 16 roles of increasing commercial responsibility, where he led global and regional sales and strategic business development. Dean has built cross-functional teams spanning all therapeutic areas. Following AZ, he grew STEM Healthcare North America from 10 clients to 38 over a five-year period before a sale to UDG. He is also a podcaster, speaker, and published author.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Brett Alderson, President and Site Leader of Novacina.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Brett, covering:

• The complexities of being on the inside of big pharma looking to carve out your site... then transitioning into a customer-facing CDMO
• Leaning into the freedom and liberation of having the shackles off as an independent business
• Pairing world-class, complex commercial capabilities (100 million+ units) with a small scaler clinical offering
• The uncertainty and capacity concerns on the market after that market-shaking deal
• And just why Australia is a hub for global for clinical trials...

Brett Alderson is a seasoned veteran in the pharmaceutical industry predominantly working with the manufacturing of sterile injectables. Brett is a determined and thoughtful leader adept at driving business success and leading through change. He is a champion for customers, instilling a customer-centric culture with transparency and helpfulness. 

He enjoys mentoring and nurturing a diverse workforce with a clear imperative of open and honest communication. Brett has a reputation as an energetic problem solver, acting with integrity and care, and always encourages solutions for a brighter tomorrow by empowering people.

Brett’s career includes more than 25 years at Pfizer, before becoming President and Site Leader of Novacina in April 2023 where he oversaw a 500-member team and the production of more than 300 Oncology products plus several additional sterile injectable medicines for local and global markets.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bruce Thompson, CEO of Kincell Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bruce, covering:

• The daunting and exciting prospect of launching a CDMO spin-out focused on early-phase companies
• The challenges and opportunities of pivoting a facility from innovator-owned to CDMO-owned
• Navigating from technical leader to a first CEO role... and the importance of covering your blind spots
• Why Bruce is seeing an upturn in the market and the emergence of more diverse opportunities.

Bruce is the CEO of Kincell Bio, bringing over 28 years of experience to his position. Before this, he was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped build the development and GMP manufacturing capabilities and served as a technical advisor internally and externally.

He has over 18 years of CMC strategy, product development, and cell therapy manufacturing experience. In his first startup role, he was Vice President of Process Sciences at Lyell Immunopharma, where he was responsible for Process and Analytical Development and tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Prior to Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He was responsible for supporting >15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs.

Bruce also spent nearly ten years at Pfizer in the Pharmaceutical Sciences division, and he received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University, and a Ph.D. in Microbiology and Immunology from the University of Louisville.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michelle Duggan, Inward Investment Manager, Invest North East England.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michelle, covering:

• Why is North East England becoming a UK hot spot for Health and Life Sciences.
• Collaborating and breaking down barriers to help create a super cluster of life sciences.
• The academic and industrial heartbeat that makes the region so attractive to CDMOs and major supply chain players.

Michelle Duggan has been an inward investment manager at invest North East England since January 2021. In 2016 to 2020 she was previously appointed as Partnership manager of Newcastle University where she was responsible for cultivating and maintaining relationships among business partners. 

Her devotion to the North East is unmatched across her extensive career. With her other previous position as economic advisor at North East Local Enterprise Partnership she helped place where businesses invest, grow and prosper - delivering more and better jobs for everyone.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Doctor Eric Edwards, Co-Founder and CEO at Phlow.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Eric, covering:

• How a life-threatening allergy for him and his identical twin brother led to a career in medicine and then an entrepreneurial journey in the pharma space
• The journey from inventors to becoming a commercial pharma company... followed by a $310m exit
• How a plan to support a shortage in critical medicines for children took a turn as the COVID-19 pandemic arrived
• The US Government awarded a $899m contract to help rebuild the domestic industrial base for Covid medicines and longer-term advanced manufacturing
• The paradox of innovative, specialty, expensive medicines vs. drug shortages for basic essential medicines that everyone should be able to access

As CEO, Eric has assembled a world-class team committed to providing a solution to the broken essential medicines supply chain and the overreliance on foreign manufacturers for the US' highest priority medicines.

He previously co-founded Kaléo, where he held several executive management positions, including Chief Science Officer, Chief Medical Officer, and Vice President.

Dr. Edwards is the co-inventor of multiple marketed products for treating allergic emergencies (anaphylaxis), named on over 215 issued and patent-pending applications.

As a Doctor of Medicine and a Biology Ph.D. in Pharmaceutical Sciences, Eric also continues to serve his community by volunteering on a local rescue squad. This includes responding to 911 calls and training paramedics in pre-hospital emergency care.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Sabina Ouimet-Storrs, Principal at GHO Capital Partners
• James West, Managing Director at Lincoln International
• Derek Hennecke, investor and board member in biopharma and cell therapy manufacturing

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests, covering:

• The year of the failed process in 2023...
• Which sub-segments of the pharma services ecosystem are hot right now?
• A myriad of buys and builds, carve-outs, and platform deals
• An optimistic outlook for the year ahead... despite some significant market headwinds

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Ferguson, Chief Executive Officer at Medix Biochemica. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:

• The positive and negative impact of Covid-19 on the diagnostic sector. And the need for more spend on diagnostic sector moving forward.
• How his humble and grounded upbringing gave him an early respect for the strength of women and gender equality.
• Simply the importance of having fun, enjoying yourself and making a difference at work. Otherwise, what’s the point?
• The importance of creating visibility in a fragmented segment of the outsourcing space and then overlaying relevance to the buyer.

With around 25 years’ experience in the life science sector, Steve has worked for the likes of Lundbeck and Thermo Fisher before joining Medix Biochemica at the CEO. He is an expert in the pharma and diagnostic space and well-respected industry leader.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chuck Frey, VP Scientific Affairs at Coating Place. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chuck, covering:

• The backstory to Wurster coating technology and how it changed the world of formulation development.
• Being the go-to guys for the most challenging processing projects... when no one else in the market can.
• The advantages and disadvantages of going under the radar.
• Ups, downs, sacrifices and successes of family life while working in the industry.

Charles (Chuck) Frey is the Vice President of Scientific Affairs at Coating Place, Inc., a CDMO focused in Wurster (bottom spray) fluid bed coating and associated services.Chuck moved on to Coating Place, Inc. in 1999 to develop expertise on the Wurster fluid bed coating process. During his time at Coating Place, Chuck has focused primarily on application of the Wurster process and related technologies to meet the feasibility, formulation development, scale up, validation, and commercial processing needs of clients. Primary interests have included both formulation chemistry and optimization of process dynamics. The company continues to manufacture proprietary Wurster coating equipment for its operations and Chuck has helped maintain and expand the company’s offer with new fluidization plate designs, new nozzles, enhanced scaling knowledge, and other technical advancements. Having spent over 30 years in the sector, Chuck has also lectured on the Wurster process and formulations, and contributed several book chapters on the fluid bed coating processes and formulations.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Event season is truly well on its way and where better to start than Swiss Biotech Day, the leading biotechnology conference in Switzerland. Renowned for its innovative biotech start-ups and big pharma companies all in attendance, it was a great chance to meet experts from the life science industry from across Europe. Which is why it should come as no surprise that your host Raman Sehgal brought Molecule to market once more to the event space.

If you loved the ‘Memoir of DCAT 2022’ episode, this is a pod for you as he hit the event space again in style and interviewed some more great guests along the way. Listen to a diverse range of our guests’ thoughts during this event.

• Richard Collins, Managing Director Bio2Business Ltd
• Hanns-Christian Mahler, CEO at ten23 health
• Stefano Console, Founder & Senior Advisor at Oriento SA
• Philippe Tschopp, Head of Business Development CDMO Glatt

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Magnus Gustafsson, formerly at the time of recording Head of Global Business Development now Chief Business Officer at Biovian.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Magnus, covering:

• The advantages and disadvantages of viral vector products, including the challenge of needing to balance cost with patient access.

• Insights into a CDMO with a 96% staff retention rate and an enviable NPS score.

• The ballooning opportunity that exists in the viral vector space but also the risk that potentially comes along with such a popular platform.

• What makes Finland and the Nordic region so special?

Magnus Gustafsson has worked in the biopharma manufacturing space for over 20 years. He holds an MSc in Biochemical Engineering, an MBA in Business Administration and a PhD in Medical Protein Science. Having worked for the likes of AZ, GE, Recipharm and Cobra Biologics, he has a track record of driving business with both commercial and strategic success combined with a customer-centric mindset. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Bigelow President at xCell Strategic Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The transition from being on the big pharma sponsor side at Pfizer to being head of one of the world’s biggest CDMOs.
• The challenging of adding a development capability to well-oiled manufacturing infrastructure and way of working.
• They key buying criteria emerging pharma considers when choose a CDMO.
• Increasing consolidation and fragmentation in today’s outsourcing sector due to continued market growth and the explosion of new technologies.

Pete is a very well respect industry leader having spent over 25 years in the global pharmaceutical manufacturing space. He was at Wyeth and then Pfizer for the best part of 15 years before becoming the interim CEO and President of North American operations at Patheon. He since moved into management consulting before establishing his own firm called xCell in 2014.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the last 12 months in the life science industry.

He covers his 5 key trends from the year including:

• The biotech capital market slowdown and its impact on the outsourcing space
• Sustainability as the hot topic within the sector, from events to company practices
• Businesses operating in an increasingly digital way and what that means for the tech companies supporting them
• The cooling of mergers and acquisitions activity in the life sciences industry
• A reduction of discussion around Covid-19 as it moves into the sector’s rear view

Come back in 2023 for brand new episodes with great guests, including a special 100th episode celebration. Also, if you’re a previous guest, keep an eye out for an exclusive invitation in your inbox very soon…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tom Moody, Vice President of Technology Development and Commercialisation at Almac.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• 20 years at Almac and being on a journey that has seen the company go from a few hundred staff to over 5500 people.
• The chemistry of today is not the chemistry of tomorrow, including the future impact of flow chemistry and the need to bring new technologies together.
• The importance of giving back to the community and inspiring the next generation of scientists.
• Reinventing yourself as a way to keep you on your toes

Prof. Tom Moody is the Vice President of Technology Development and Commercialisation at Almac Sciences. His work has earned him numerous accolades and he is co-author and author of over 60 publications and patents. He is a strategic leader and technical expert in chiral chemistry and biocatalysis with more than 20 years of extensive academic and industry experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Terry Novak, President & Chief Executive Officer at Salubrent Pharma Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Terry, covering:

• What he has learnt from 40 years in the pharma, biopharma and contract services space
• The best marketing technique - communicating constantly to your internal audience.
• The wave of orphan drugs that are driving demand for small scale and flexible manufacturing capabilities.
• How a focus on talent is going to make or break companies in the next 3-5 years.

Terry has extensive CDMO C-suite execution experience serving in numerous capacities. Terry has served on the Board of Directors of Pernix Therapeutics Ireland, Percivia LLC, American Red Cross Northern NJ Division, Patheon Puerto Rico, Frontline Pharmaceuticals, Curaxis Pharmaceuticals and is currently on the Board of Directors of Salubrent Pharma Services and Minutemen Life Sciences. Operationally, Terry has served as the CEO of Tedor Pharmaceuticals, COO of Pernix Pharma, President of Norwich Pharmaceuticals, President of Patheon North America, President of Frontline Pharmaceuticals and President of DSM.

During his 40 years in industry, he had built a track record of rapid turn-around success includes achieving consistent double-digit growth in revenues and EBITDA.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Shawn Singh, Chief Executive Officer and Director at Vistagen Therapeutics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Shawn, covering:

• What life is like running a public company and how that is impacted depending upon the season of the capital markets
• The ups, downs and pivots of a biopharmaceutical company that’s led it down a mission of transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders
• How the pandemic has magnified mental health issues and their prevalence among young people, and why finding a radically social transformative treatment is needed
• Why collaboration is key when developing several drug candidates and how partnerships can happen at any stage of the lifecycle
• His views on CROs, CDMOs, what is essential to outsource in the vendor universe... and the most critical asset to a biotech boss

Shawn is an experienced public company Chief Executive Officer and Director. He has over 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles.

He’s an attorney and a member of the California State Bar with a Juris Doctor from the University of Maryland Francis King Carey School of Law.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Louise Duffy, Ph.D., SVP and Head of the Scientific Project Leaders at Abzena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Louise, covering:

• Learnings for CDMOs after almost three decades spent with big pharma. 
• How to balance the juggling act between dealing with hundreds of projects, clients, and systems as a fast-growing large molecule CDMO.
• Why the speed of innovation has massively increased in pharma and biopharma over the last 10 years.
• Tips on how to improve your presence and move forward quicker as a female leader.
• The importance of closer-knit supply chains involving originators, CDMO, technology, equipment, and material providers in developing increasingly complex molecules.
• The trend towards customised molecules with exquisite targeting and greater government interest as consequence of Covid.

Dr. Louise Duffy is a Senior Executive with an extensive background in the global bio/pharmaceutical industry with experience in business development, strategy, R&D, operations, and supply chain. She has more than 30 years’ experience in the industry, including increasing responsibilities at GlaxoSmithKline and Janssen. With broad CMC and regulatory experience and specialist knowledge in personalised medicine, biochemical engineering, chemistry, and biological sciences Louise is SVP and Head of the Scientific Project Leaders at Abzena.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Charles Ruban, CEO at Verdot.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Charles, covering:

• Crossing the border from supply chain to R&D, lessons learned from a technician turned business leader
• Creating the most extensive peanut allergy clinical trial in the world and opting for an IPO instead of a big pharma licensing deal
• How a call from a PE firm led to a spectacular exit
• Designing and creating downstream bioprocessing equipment in a Patagonia-inspired way - intelligent, sustainable, and functional - is critical for the future
• Why you need to know several biopharma trends, including AI, China R&D, and the fastest-growing therapeutic segment... you need to know

Over the last 25 years, Charles has held rich and diverse executive leadership positions in fast-growing international healthcare companies. His experience includes Manufacturing, Research and development, Business development, and Global Management in biotechnology and biopharmaceutical companies.

Charles is the CEO of VERDOT, a key player in bioprocessing, serving advanced solutions to the biotechnology and biopharmaceutical industry worldwide. Before this, he was the co-CEO at HTL Biotechnology, COO of DBV Technologies, and also spent considerable time at Eurogroup Consulting and Stallergenes.

He has been instrumental in streamlining supply chain operations, establishing strategic alliances, developing and launching therapeutic biologics in Europe, the United States, and Japan, and performing business activities. He has been heavily exposed to investors in both public and private environments.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hans J Johansson, Global Applications Director at Purolite. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hans, covering:

• A career spent developing ideas and creating products that produce new applications for customers and commercial success.
• Driving the Purolite business unit from the ground-up from a lab bench to a commercial scale life science based franchise.
• Hans’ lifelong habits and approach that have enabled him to have a successful career.
• An insight into Sweden’s vibrant life science hub - Uppsala.
• The development of new technologies that will increase yield while reducing environmental footprint... a sign of things to come!

Hans J Johansson is Global Applications Director at Purolite Life Sciences, Llantrisant, Wales. He has spent more than 30 years in the Biotech industry. Most of the time in research and development at Pharmacia/Amersham/GE Healthcare with a special focus on design and applications of industrial chromatography resins intended for antibody purification. He frequently publishes in scientific journals and is the holder of more than ten patents around resin design and large-scale protein purification. He is currently working with development and applications of novel, agarose-based, chromatography resins.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tushar Misra, Chief Manufacturing Officer at Mersana Therapeutics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tushar covering:

• How his opportunistic nature led him to several roles, companies and locations across the processing and biopharmaceutical sector
• Being given the task of building a worldwide manufacturing and supply chain infrastructure for the commercial launch of a biologic oncology product globally for Takeda
• Key components of a strong CDMO partnership ‘beyond checking boxes’ and how the type of product impacts the selection process
• The harsh realities of a recent clinical failure for a biopharmaceutical company that impacts employees and patients
• How the explosion of modalities have driven growth across all segments the outsourcing space

Tushar Misra is the Chief Manufacturing Officer at Mersana Therapeutics, a biopharmaceutical company specializing in the discovery and development a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. He has over 30 years of experience in developing drugs that involve small and large molecules and ADCs, as well as the development and management of worldwide commercial supply chains.

Prior to Mersana, Tushar was EVP, Head of Technical Development & Manufacturing at Laronde, where he led the process development and manufacturing team for end-to-end manufacturing for RNA products. In addition, Tushar worked at Takeda Pharmaceuticals in several positions of increasing seniority, most recently as VP & Head, Global Oncology and Biologics Operations.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Go van Dam, CEO & Founder at TRACER.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Go, covering:

• The value of micro-dosing and fluorescent imaging in small patient populations at the preclinical proof of concept phase, and the benefits to investors, biotech and big pharma.
• The journey of stepping out of the operating theatre and into the boardroom. Taking an idea from the academic breeding ground and scaling into an industrial level so it has greater application.
• How the academia and industry ecosystem can collaborate, share and partner for the greater good.
• The need to observe, talk and learn from others. And it’s OK to copy and paste what you like in others.

Prof. Go van Dam is the CEO and Co-Founder of TRACER, a Clinical Research Organisation specialising in generating fast and accurate in-human data with nuclear and optical molecular imaging techniques, even before the classical Phase I-III studies. Go is seen as a pioneer in the optical imaging field with groundbreaking research to his name. 

Go originated as a surgeon oncologist and professor of Surgery at Groningen University. He trained at Harvard, the Mayo Clinic and NCI. Go executed and published the 1st in-human application of targeted fluorescence imaging in 2011 (Nature Medicine) and published more than 140 papers predominantly about clinical translation of innovative targeted optical molecular imaging. He currently focuses on utilising his validated optical imaging expertise in the life sciences industry to reduce R&D innovation costs, shorten time-to-market, and increased efficiency for innovative drug development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeffrey Kiplinger, Co-Founder of Cohere Business Strategies and advisor and coach for entrepreneurs in the life science space. Jeffrey Co-Founded Research Operations Group in 2000, founded Averica Discovery Services in 2007, and has over 35 academic publications and holds a PhD in organic chemistry. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Jeffrey Kiplinger as he describes the benefit in making oneself vulnerable and putting your pride aside to seek the support of others. He advises young leaders to ask “stupid questions” and allow your mistakes to become a part of your success story. Jeffrey speaks about the changes he has seen in the sector over the years and the interesting shift towards a numbers-based system which in his opinion, has devalued the scientists at the core of operations. As a coach for entrepreneurs, Jeff covers the barriers many business professionals face when trying to start their own business in the life science sector. He offers advice and words of wisdom for those who are struggling in this difficult market. Lastly he stresses the value of the relationship with a client and explains how it can be the key to success in this industry.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tia Lyles-Williams, CEO of LucasPye Bio. Tia is the first African-American Queer Woman to own & lead a Biopharma Large-Scale Manufacturing Company in the US. She has spent 20 years in the industry formerly working for the U.S. Federal Government, Big Pharma and Small Biotech Companies, before setting up her own CDMO. Tia is not only highly knowledgeable about the biotechnology sector but she works hard on helping economic development in underserved communities.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tia, covering how equality and diversity in the pharma and biotech space is no better now than it was 20 years ago, which is being compounded by Covid-19. She describes the challenges of fundraising and getting a biotech CDMO built and off the ground in an economically underserved community in Philadelphia. She stresses the importance in young people taking their education and experience into their own hands and going the extra mile to unlock new opportunities, “don’t ask permission to lead” she says. Lastly, Tia speaks on creating a new breed of CDMOs, organizations that are highly digital, leaner, faster, cheaper, and more transparent with a social conscience. She also wants to put Pennsylvania on the map as the next major global life science biotech hub.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal, Founder & Global President at ramarketing & Host of Molecule to Market.

For this milestone episode, your host is Molecule to Market’s first guest from back in 2020, JoyL Silva, Customer Engagement Lead for the US Primary Care portfolio at Pfizer, who discusses the pharmaceutical and biotechnology supply chain with Raman Sehgal covering:

• Raman reflects on the podcast’s evolution, from its inception during COVID-19 to becoming a globally recognized platform
• They discuss key trends in the pharma outsourcing sector and the impact of guests who have contributed to the podcast’s success
• Raman shares highlights from his career, including the growth of his companies, ramarketing and Lead Candidate, and his private equity ventures
• Insights into balancing work and family life, with advice on being present and managing priorities
• A desert island question where Raman chooses which podcast guests he’d bring along, plus behind-the-scenes stories of challenges and humorous incidents

JoyL Silva is the Customer Engagement Lead for Pfizer’s US Primary Care portfolio, overseeing sales and account management across therapeutic areas such as Migraine, Cardiovascular, Anti-virals, and Vaccines. She leads high-performing teams that drive a $20B portfolio through agile methodologies and talent development. With over 20 years at Pfizer, JoyL has excelled in commercial leadership, business transformations, and operational expertise, delivering impactful results across multiple roles, including VP for Hematology and Biosimilars, General Manager of Pfizer CentreOne, and US/Global Commercial Lead for PAXLOVID, where she spearheaded global strategies and partnerships for Pfizer’s COVID-19 antiviral therapeutic.

JoyL frequently speaks at industry forums and contributes her expertise to various publications and professional boards, including the Pharma & Biopharma Outsourcing Association. Her accolades include being named to the Medicine Maker Power List and PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry, as well as receiving awards such as the Scrip Best Partnership Alliance Award and Putnam Media Top 20 Influential Women in Manufacturing. Her career reflects a strong commitment to driving innovation and fostering leadership in the life sciences sector.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Bottome, a global supply veteran.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering:

• Stretching yourself by tapping into the collective wisdom of others
• The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D
• The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company
• Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully

Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin).

He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Elisabeth Stampa, President Medicines for Europe and Board Chair at Medichem.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Elisabeth, covering:

• She took the reigns of the family pharmaceutical firm from her father
• The struggle of turning around the business through rationalization and divestment and critical lessons learned from a tricky time
• Re-building into a multi-national, $140m+ API and FDF CDMO with flexibility at its core
• Insights into future trends will impact our space, including the aging population, reliance on Asia, and the need for patient affordability to access medicines

With over twenty years in the industry and an experienced business leader with a track record in growing and transforming businesses, Elisabeth serves on the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player.

A pharmacy graduate by trade, she also serves on the Board of Trustees at the IQS in Barcelona and is President Medicines for Europe. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry globally.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this special end-of-year episode, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the 50+ episodes and special guest interviews throughout 2023.

In the second part of our series on the top trends 2023, we dive deep into the dynamic and ever-evolving life sciences sector. From its various life cycles to the winds of change shaping the industry in 2024, there is a positive upturn on the horizon.

In part two of the top trends from 2023, Raman identified trends including:

• How the M&A market has suffered in a fractured CDMO space over the last 12 months
• The new breed of biotechs coming to the life sciences market and what they are doing differently to be slimmer and more capital-efficient
• The rise of artificial intelligence and the importance it will play in the digitization of the sector 
• Why adaptability and flexibility are causing a sizable impact on an uncertain financial market in the life sciences sector
• Why the term “Green Shoots” is back in the life sciences vocabulary 

Catch up on Part One! 

Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason C. Foster, Chief Executive Officer and Executive Director at Ori Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering:

• How being frustrated by big company life led to the development of a business unit within Reckitt Benckiser that went on to be valued at $1bn
• The story of how a spin-out went on to list on the LSE with a cool $3.5bn market cap
• Taking his skills and experience before making 18+ healthcare start-up investments,... determined to add value beyond the cash
• Being wowed by the potential of CGTs and building the business he always wanted to work for in Ori

The mission is to build enabling technology for power cell therapy companies and cut down the manufacturing costs by at least 50% to improve accessibility and affordability.

Jason has held leading roles in consulting, healthcare and technology companies for over 20 years in the US, UK and Europe. He is CEO and Executive Director for Ori Biotech, a cell and gene therapy manufacturing technology start-up with offices in London and New Jersey.

He raised a $100M Series B funding round in December 2022. Jason also serves as a Non-Executive Director of London-based health tech start-ups gripAble and Credentially and Auxita Pty, an Australian healthcare data platform. As the Managing Director of Health Equity Consulting, he has advised PE/VC funds, family offices, accelerators and healthTech start-ups.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ian Tzeng, Managing Director at L.E.K. Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering:

• Insights, trends and advice for CROs, CDMOs and pharma services firms from one of the most prominent life science consultants.
• What he gained from his time studying at Harvard and the importance of genuine curiosity and a multi-disciplinary way of thinking.
• The complexity of modality and technology fragmentation, and the challenge of picking the right ones from a CDMO perspective.
• Why focusing on ‘conserved areas’ and ‘platform technologies’ could be a smart move when thinking about diversification and long term investments.
• The shift we are seeing from volume-based blockbuster drugs that deliver billions of pills to the masses, to targeted speciality drugs, to even more advanced therapies for micro-patient populations.

Based in the Boston, Ian has 20+ years of consulting experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He directs projects across the healthcare spectrum with particular emphasis on Biopharmaceuticals & Life Sciences and MedTech practices.

As a focus area, he leads L.E.K.’s pharmaceutical contract services practice. Additionally, Ian has extensive consulting and board experience with non-profit organizations in education, arts, LGBTQ+ advocacy, and public service. He received a Bachelor of Arts degree, magna cum laude, in Chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gerry, covering:    

• The transition from two decades in Big Pharma to the entrepreneurial world of running a CDMO.
• Becoming known as the ‘lab down the hall’ for many clients with products in the clinical phase of development.
• The value of talking to people, networking and not being intimidated when starting out your own business.
• Consistently keeping your operational house in order in the face of increasing market demand.

Raman has taken great pleasure in getting to know fellow Bostonian Gerry, since moving to the states. An accountant by trade, Gerry worked for Pfizer for eighteen years in corporate and research & development roles, both globally and onsite. Since founding Velesco back in 2007, he has led the steady growth of the company’s operations and its most recent expansions. A phenomenal networker, Gerry enjoys connecting people and communicating with people within the sector.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Detlef Behrens, founder at Bay Pharma. A PhD pharmacist by training, Detlef is a seasoned industry professional having spent 20 years in the pharmaceutical and biotechnology space. He’s worked for several global CDMOs and now runs a biotech company. He is one of a rare breed that has seen drug development from both the CRAMS/CDMO/CMO vendor side of the fence and the sponsor side. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Detlef, speaking on what life is really like in a small virtual biotech company, how the pharmaceutical industry and its supply chain will evolve as a consequence of the current/ future pandemics and the role of a global one-stop shop CDMOs versus specialist companies. Detlef also explains the importance in disrupting the way we have done things in drug development in the past.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Richard Weaver, Founder and Managing Director at Drug Discovery Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:

• How his curiosity to learn at AZ led him to realizing he was an entrepreneur
• The opportunistic start-up story and impressive growth journey of XenoGesis up to the eventual, successful sale to Sygnature Discovery in 2020
• Lessons learned and milestone moments of a scientific entrepreneur
• Why biotechs are here to stay... outsourcing is here to stay... but why offshoring is not

Richard is Founder and Managing Director of Drug Discovery Solutions Limited. Previously CEO and founder of XenoGesis, he grew and led the successful sale of the business to Sygnature Discovery in 2020. Prior to that, he spent 14 years at AstraZeneca.

He is an expert of all aspects of R&D including Due Diligence of companies/assets. Specialist in Drug Metabolism & Pharmacokinetics (DMPK) from Hit Identification (HI) to Candidate Drug (CD) nomination and pre-clinical development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with  Ian Walters, CEO and Chairman at Portage Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering:

• What Ian learned from his time working with a team of Nobel Prize winners at Rockefeller University
• Breaking the mold by launching a clinical trial in just three months versus the 12-month standard in a big pharma firm
• Why building relationships with big pharma is key as a small biotech company with multiple assets in the pipeline
• How his lean biotech is running the most rapid proof of concept studies in the market whilst conserving cash and building value
• Why manufacturing and reliance on CDMOs have been the biggest challenge to his business

Dr Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases. 

Prior to Portage, Ian spent seven years at Bristol Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds and biomarker and companion diagnostic work. He was a core member of Bristol Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations and the company’s immuno-oncology strategy. Prior to BMS, he held positions at PDL BioPharma, Inc., Millennium Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs.

Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated advanced immunology research to understand the mechanism of action of several compounds. Ian received his M.D. from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with  Barbara Morgan, Global Business Director for Pharma and Nutra at Lubrizol. A PhD chemist by trade, Barbara has gone from working at the Broad Institute of MIT and Harvard in 2009, to heading the CDMO and Nutra division of Lubrizol, an incredible trajectory in 10 years. Along the way, she’s headed up teams, worked in the VC/M&A space and held a variety of very interesting roles in healthcare.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Barbara Morgan, covering why it’s essential for pharmaceutical leaders to build a diverse team and the value of having mentors and sponsors both at work and outside of work. They also discuss how holding a variety of roles over time, constant learning and taking risks can help accelerate your career in the pharmaceutical industry. Lastly they speak on the increasing importance of bioavailability in modern drug development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tessa Pugh, ex-CEO & Co-Founder at PharmaReview.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering:

• How Tessa's bullish attitude led to her becoming a co-founder at PharmaReview
• Being the 'less educated person in the office', and using that to drive the growth of the business
• Opting not to leave after the sale of the business, and becoming the CEO
• Being the star player within a PE portfolio, leading to a quick exit to IQVIA
• Life lessons on having your cake...and eating it!

Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality.

Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world’s leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Eugene Ciolfi aka ‘Gene’, President and CEO at MedPharm. Gene has spent over 30 years in the CDMO space working for several renowned companies in senior roles along the way. It’s fair to say Gene has probably seen more than most in drug development!

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gene, speaking on the transformation of the CDMO landscape over the last 30 years. They  address the many changes that have occurred but also the things that have stayed the same as time goes on. They also discuss the benefit of truly ‘value-add’ CDMOs to small and large drug developers in helping achieve pipeline success and raising the CDMO bar. Lastly Gene discusses the importance of being okay with making mistakes and addresses trust and integrity as two key pillars in the heavily regulated pharmaceutical and biotech drug development space.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with part 1 of our episode with Thomas Eldered, Executive Chairman at Flerie.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• Where his entrepreneurial spark originated, and how they created a CMO (before that was even a thing) after several failed plans
• How did the timing of his first exit and having ‘cash during the crash’ fuel M&A to grow Recipharm into an international powerhouse?
• Why did he decide to go public? No one else in Sweden or in the CDMO space was getting an IPO
• A lifetime with Lars (his business partner) and the benefit of a partnership with aligned common interest
• Why he decided to sell Recipharm after 26 years and why leaving the company was the most difficult mental decision

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries. He also founded Flerie Invest AB in 2011, where he is currently Executive Chairman. Thomas is currently chairman of the board and a member of the board of several life science companies. 

He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering:

• His unusual blend of experience led to a road into big pharma...
• Switching the security of Big Pharma to join an exciting, scrappy, start-up biotech... before an exit to Roche
• Being part of the gene therapies evolution with an innovative biotech that later became Novartis Gene Therapies
• His views on the thorny issue of CGT products' price (and value)
• Opting to start his own business aimed at supporting the future of healthcare

Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry.

As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector for part 2 of our conversation with Thomas Eldered, Executive Chairman at Flerie.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• The story behind Recipharm’s decision to divest Cobra Biologics that led Thomas to become owner
• How ‘big faith’ and the gene therapy revolution changed the fortunes of the loss-making biologics CDMO
• After the third exit, why did he choose ‘passion rather than pension’? To fuel his love for creating things and building companies
• Flerie’s mission and its patient-centric investment strategy in life sciences.
• The story behind Thomas’ signature bowtie look…

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries.

He was also the founder of Flerie Invest AB in 2011, where he is currently the executive chairman. Thomas is presently chairman of the board and a member of the board of several life science companies. He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• James Edgar, Chief People Officer at Sygnature Discovery
• Andrew Mears, CEO and Co-founder at Lead Candidate
• Laura Child, Head of Research and Strategy at ramarketing

Your host, Raman Sehgal, discusses pharmaceutical and biotechnology talent challenges and solutions with his guests, covering:

• Where the industry-wide talent challenge originates, and practical solutions of how companies can take steps to overcome it
• The role of a talent attraction team, a recruitment expert, and your employer brand in getting ahead of the curve when it comes to building a people pipeline
• Mapping and flawlessly executing your employee experience value proposition when attracting, onboarding and engaging your stars
• Staff retention challenges across the board and when things go wrong with your people

James Edgar has been in post for 12 months and has joined to support the growth of the company into its next phase with the development of Sygnature’s Employee Value Proposition. He has over 20 years in the People and Human Resources field. He comes with multi-sector experience from Financial Services, Manufacturing, Facilities Management and more recently from Advertising and Media sector with WPP.

Andrew Mears is CEO and Co-founder of Lead Candidate, a specialist talent acquisition consultancy exclusively supporting the global pharma and bio-outsourcing sector. He has more than two decades of experience working in human resources and talent, developing and delivering talent initiatives to help fast-growing companies achieve ambitious change and growth agendas.

Having built an impressive career as Program Director in some of the largest multinational CROs, delivering high-value and high-complexity global trials, from Ph 1 through Ph 3, Laura joined ramarketing as Head of Research and Strategy. In this role, Laura works closely with a team of senior marketers and Sector Specialists to conduct in-depth research projects to deliver data-driven brand and growth strategies for clients.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr Camilla Easter, CEO at Oxford Medical Products.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Camilla, covering:

• Training long and hard as a Veterinary Surgeon surgeon... and then deciding to pivot into biotech
• Falling in love with the freedom and excitement of a start-up biotech while learning the importance of problem-solving and storytelling
• OMP's swelling hydrogel pill that reduces the space in your stomach and surpasses your appetite
• Developing a complementary product to GLP-1s to help tackle the 2billion+ global obesity challenge in a preventative, cheap, safe manner
• How OMPs unique, patented manufacturing process led it to in-house production and not outsourcing
• Lifting the lid on a recent selection process of choosing a global CRO partner to support upcoming clinical trials

Camilla has over ten years of biotech start-up experience as CEO and COO, working exclusively on hydrogel-based therapeutics. Initially a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following this, she moved into the human biotech sector, where she has been involved in all aspects of start-ups, including, R&D, manufacturing scale-up, fundraising, regulatory, quality, pre-clinical and clinical trials for medical devices.

Camilla joined the OMP team in 2019, initially to evaluate OMP technology. This led to the establishment of a team and the raising of the first round of external investment in 2020.

OMP has developed Sirona, which, taken as a pill, rapidly expands in the stomach to create a sustained feeling of appetite suppression. Sirona remains in the stomach 24/7 for several days before breaking down and passing naturally. Since 2020, they have completed preclinical testing and phase 1 clinical trials. Sirona is now in phase 2a for obesity at three NHS sites, with results expected in Q4 2024.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses emerging trends and challenges for the life sciences sector live from CPHI Frankfurt 2022, with:

• Grainne Hughes, Vice President of Business Support Operations at Almac 
• Christine Fürst, Senior Director Key Account Manager Europe at Vetter Pharma 
• Guido Wallraff, Corporate Business Development Director at Ardena
• Jenny Gattari, CDMO Business Development Lead (North America) at Pfizer CentreOne 
• Brittany Hayes, Director of Global Highly Potent & Oncology Platform at CordenPharma

Listen to this episode to find out more about these companies and gain an insight into the changes and demands they see coming in 2023. They also discuss their experience of CPHI this year, how it compares to last year’s event and what trends they have noticed across their exploration of the Messe. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Cook, CEO at Sterling Pharma Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:

• Decades of mixed ownership and conflicting business models led to lots of character-building learnings... and the rebirth of Sterling
• The power of a rebrand and sense of togetherness to gain commercial traction
• Kevin’s five-point M&A playbook that’s helped drive exponential, transatlantic growth
• Why culture and people are the hardest things when scaling from 180 colleagues on one site to a 1300+ strong team across six sites
• The robustness of small molecules, on-shoring back to the West and reasons to be optimistic for the future

Kevin has over 30 years of experience in the pharmaceutical industry. He started working with Robinson Brothers as an Assistant Plant Manager before progressing to Senior Plant Manager. Kevin then joined Boots Pharmaceuticals with responsibility for commissioning activities on a new pharmaceutical plant.

In 1993 Kevin joined Sterling Organics and has supported the site through several mergers and acquisitions over 18 years. At that time, he was Operations Director for Chirex, Industrial Director for Rhodia Pharma Solutions, and President of Shasun Pharma Solutions.

In 2010, Kevin joined Aesica Pharmaceuticals as the Managing Director for the API business unit with a clear focus on growth through increasing the customer and product portfolio. Kevin returned to Shasun Pharma Solutions in 2013 to take responsibility for all commercial activities relating to the pharmaceutical service business. Having overseen the launch of Sterling Pharma Solutions as an independent CDMO, he was appointed CEO, President, and Board Member.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Dexter Tjoa, Chief Executive Officer at Tjoapack, Erik Haeffler, VP Manufacturing Services & Head of Sustainability at Recipharm AB, John Ross, President at Mayne Pharma and Metrics Contract Services, and Mark Emalfarb, CEO, Board Member and Founder at Dyadic International, Inc.

During this discussion we will explore two angles to driving efficiency, diversification vs. development of specialism. Emerging trends include the move to manufacture multiple technologies under one roof, at the other end of the scale we see companies staying true to original areas of expertise in order to refine and grow.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences. 

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering:

• How a family ritual of solving puzzles played a role in developing an entrepreneurial spirit of problem solving
• Learn about how and why Northern Texas is becoming a destination for biotech and life sciences
• Going viral for being viral... and why covid was the time for immunologists to shine
• The opportunities and challenges of introducing innovative, disruptive technology into the biopharma space

Claire Aldridge, Ph.D. is Chief Strategy Officer for Form Bio, the first spinout from the de-extinction and biodiversity company, Colossal Biosciences. Prior to this role, she was Senior Vice President, Chief of Staff and Corporate Strategy at Taysha Gene Therapies, a Dallas based company focusing on eradicating monogenic CNS disease. She previously served as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center and VP, Venture Development with Remeditex Ventures, a local biotech venture fund.

Dr. Aldridge brings more than 20 years’ experience facilitating the translation of scientific discoveries into patient and commercial benefits. Dr. Aldridge is also on the Scientific Advisory Board for Colossal Biosciences, the Board of Directors for MedCognetics and 4E Therapeutics and is the chair for the Industry Advisory Council for the UT Dallas Department of Biomedical Engineering. Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this mid year episode special, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the trends happening across the life sciences and outsourcing space in 2024. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain covering: 

• The anticipated recovery of the biotech sector and where it stands now
• Geopolitical influences on the life sciences industry, with a focus on the CDMO sector
• Exciting upcoming episodes and insights to watch for in the next few weeks
• Where to meet Raman at upcoming trade shows across North America & Europe
• Sectors powering through industry challenges, including early-stage development and AI-driven drug discovery

Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jitesh Devendra, Managing Director at Solara Active Pharma Sciences. As former president of Shasun Formulation Jitesh has 20 years of experience in managing sales and business development both on API's and Formulation. Originally from Chennai, India, Jitesh has traveled the world and gained much experience along his journey. 

Your host, Raman Sehgal, and guest, Jitesh Devendra discuss the pharmaceutical and biotechnology supply chain and predict the key trends and the risks we face in the sector as the supply chain becomes more sensitive due to the current climate. Jitesh offers advice to young professionals, explaining the importance of keeping an open mind, embracing challenges and new opportunities in life and how it is crucial to invest time internally to be just as operationally focused as you are strategically focused. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We would also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering:

• Growing a CDMO while dealmaking in a gene therapy company…at the same time
• Selling a revenue-generating therapy company to Bayer during the pandemic
• Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it’s going to save lives
• The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table 

Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma. 

Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio’s manufacturing expertise for clients around the world.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michael Quirmbach, Group Chief Executive Officer and President at Corden Pharma. Michael has been in the contract services space for 20 years. He joined Corden Pharma in 2014, holding positions as Vice President, Marketing and Sales and Chief Business Officer before becoming CEO & President in 2019. Prior to joining Corden Pharma, he held positions of increasing responsibility at AMRI, Solvias, Dr. Reddy’s and Siegfried AG.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Guest Name, Michael, covering manufacturing and supplying front-line drug products in the fight against Covd-19. They speak on transitioning a big pharma cost/profit centre mindset culture to a more agile, customer-centric, resilient, CDMO service mentality. And finally they discuss the role of continuous education, openness to cultures, goal setting and daily routines in achieving incredible career success.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, we do things a little differently with an experimental episode. You’ll go inside the outsourcing space of the global drug development sector with the best-selling sales author, Ian Altman. 

Ian started, sold, and grew his prior companies from zero to over one billion dollars in value. He’s a co-author of the bestseller, Same Side Selling, now in its second edition. He is the author of hundreds of articles on Forbes and Inc. Ian is recognized as one of the world’s Top 30 Global Gurus on Sales, and his Same Side Selling Academy is ranked in the top 5 globally for Sales Development Programs.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Ian Altman discussing “becoming a magnet for your client’s problem” while also making sure the client has a problem worth solving. Ian speaks on the importance of role-playing, practising and rehearsing sales scenarios. He explains the need to aim for the ‘engage’ level with potential clients in order to secure the next pharma or biotech deal. Lastly, Ian explains the importance of understanding your client’s Elevator Rant and the emotion and impact of not solving their issue.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeffrey P. Kiplinger, Partner at Selling Science.

Your host, Raman Sehgal, sits down with Jeff to discuss his new book, 'Expert to Entrepreneur'. 

Jeff Kiplinger is a PhD chemist who, after leaving a scientific leadership role at Pfizer in 1998, transitioned to business leadership and an entrepreneurial track. In 2007 he founded Averica Discovery, an analytical drug development CDMO in the Boston area. With solid growth in a tough economy, Averica was an attractive target and was acquired by a Canadian lab services company.

Jeff left in 2018 and wrote about the experience of changing focus from science to business in his new book, “Expert to Entrepreneur: How to Turn Your Hard-Won Expertise into a Thriving Business”, which made the Amazon Bestseller list in its first week.

Jeff is passionate about helping scientist entrepreneurs build their businesses. He’s a keynote speaker and coach, leads mastermind groups for scientific founders, and is a co-creator and partner in Selling Science, a consulting firm that helps companies grow their revenue by developing successful sales programs. He still lives in the New England area with his wife Katy, and spends most of his free time outdoors hiking and cycling.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Ross Burn, Chief Executive at CatSci
• James Hales, Senior Director at NorthEdge
• Tom Cowap, Managing Director for Pharma Services at Baird

Your host, Raman Sehgal, discusses pharmaceutical and biotechnology supply chain M&A activity with his guests, covering:

• How the market headwinds, continued consolidation and macro slowdowns are impacting M&A activity in our space... if at all...
• Why PE is still very keen on the pharma and biotech ecosystem and why the size and shape of deals and investments in the market have changed.
• How an investment is enabling Ross’ business to accelerate growth in several directions.
• A look forward to geographic shifts, continued biotech outsourcing, and how there maybe riches in the niches of sub-segments of the pharma services ecosystem.

After completing his PhD in 2007, Ross joined AstraZeneca as a Senior Analytical Chemist in process R&D. Ross’ analytical expertise and entrepreneurial mindset was pivotal to the establishment of CatSci Ltd in 2011. Ross became CEO in 2015 and has since led the company’s pivot from a catalyst screening company to the award-winning innovation partner for medicines development that it is today. As such, Ross was included on the 2021 edition of The Medicine Maker’s annual Power List of inspirational professionals in the pharmaceutical industry. CatSci received PE backing in 2022.

James is a Senior Director at NorthEdge and leads the healthcare origination efforts as part of the wider healthcare sector team. He is fortunate to meet with management teams nationally across a number of sub-sectors to understand their plans and to identify new investment opportunities for NorthEdge via growth and development capital, management buy-outs, equity release and buy-and-build opportunities. Prior to joining NorthEdge, James spent seven years in Corporate Finance at Clearwater International where he was a Director responsible for generating mid-market opportunities and managing the Deal Origination team.

Tom is a Managing Director in Baird’s European Healthcare Investment Banking team. Tom joined Baird from Alantra where he spent nine years building Alantra’s pharma services coverage effort, providing M&A services for financial sponsors and independently owned, founder backed businesses in the space. Prior to Alantra, Tom worked at PricewaterCoopers in their Financial Due Diligence team. He also served in the British Army (Reserve – 7th Battalion, The Rifles and 4th Battalion, The Yorkshire Regiment). Tom is an ACA and had a bachelor’s degree in finance from Durham University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Himanshu Gadgil, CEO at Enzene Biosciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Himanshu, covering:

• How a personal tragedy led him from the US to India on a mission to make an impact
• Shifting from a technical to commercial focus to launch several biosimilars in India and beyond
• Being at the inception of a big pharma biotech spin-out focused on building a platform of innovation that contributes to society
• Taking its cost-effective, continuous manufacturing platform from India to the US via a CDMO vertical focused on novel biologics

Dr. Himanshu Gadgil serves as the CEO at Enzene Biosciences Ltd. Under his services, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company. Prior to Enzene, he worked as the Sr. Vice President at Intas Pharmaceutical Ltd. where he was instrumental in turning around the commercial product pipeline by launching several biosimilar products in multiple geographies.

During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA, and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation, where he pioneered the development of QBD, enabling multi-attribute methodologies for biopharmaceutical characterization. Himanshu holds a Ph.D. in Biochemistry from the University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special bonus episode of Molecule to Market, our host discusses his very first book launch ‘The Floundering Founder’ which is now available on Amazon and Kindle. 

Whilst you know him as the host of Molecule to Market, Raman has built up an impressive career in marketing, leadership and sector disciplines over the past 20+ years working within the global pharmaceutical and biotech outsourcing sector. Over the past twelve months of that career, Raman has spent an hour each day working on his latest achievement: ‘The Floundering Founder.’

The Floundering Founder gives 24 lessons to refocus your business and better yourself.  

With quick, simple lessons, The Floundering Founder can help you re-engineer your business and your life for sustainable, long-term success.

In twenty-four bite-sized lessons that fit any schedule, you’ll learn to navigate forward with renewed intentionality and purpose.

Make no mistake, this book isn’t fictional. You will relive the close and personal revelations of starting and scaling a business and how ramarketing has grown to be one of the most fast-growing global marketing agencies. 

To purchase visit:

UK link is here

US link is here

We would love to hear what you think of the book! Please write us a review to let us know what you think in the review section.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with J.D. Mowery, President and Chief Executive Officer at KBI Biopharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with J.D., covering:

• The experience of bringing a product to market... and then many years later seeing that product used on his wife to help bring his sons into the world
• How bringing a commercial facility online for Genentech to impact thousands of patients compares to the ‘vain to vain’, hospital-based, one-off patient CAR-T product for Juno
• Why the ethos of taking care of the person on your left and the person on your right helps with the scale-up of a multi-national global CDMO
• The emergence of a partnership-based, absorption business model between innovators and CDMOs in the wake of the shift in capital markets
• What the next generation CDMO will look like…

J.D. is an accomplished leader with a distinguished reputation in the biopharma industry and proven expertise in guiding global innovators and contract development and manufacturing organizations (CDMOs) for nearly 25 years.

Throughout his diverse career, J.D. has demonstrated strategic vision and the ability to drive all aspects of an organization, including operations, R&D, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. He is an expert in diverse modalities, including small molecules, biologics, and cell and gene therapy. J.D. has held executive leadership positions as 

Head of Operations at Lonza and Executive Vice President of U.S. Operations at AGC Biologics. He has also held influential roles at innovators, including Genentech, Celgene, and Juno, and most recently served as Chief Operating Officer at Treadwell Therapeutics. J.D. holds a Bachelor of Science from George Fox University and an MBA from Marylhurst University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Oren Beske, Amalgamator of Business and Biology at ATUM.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Oren, covering:

• How he ended up at Atum with one of the most peculiar job titles in the industry...
• The balance (and conflict) of combining a world-class science offering with the economic need of needing to monetise a business
• The journey from transactional, smaller deals in the pre-clinical space to powering outsourcing for biotechs
• The realities of drug development capability sharing in return for a slice of the profit pie, and its upsides when it comes to a CRO vendor and drug sponsor model

Dr. Oren Beske joined ATUM in 2019 and brings over 20 years of industry experience to the team. After receiving his Ph.D. in Cell Biology at UCSF, he led a biology team at an automated microscopy start-up that was developing solutions for the high throughput, high content screening industry. Having spent over five years there he moved from product development to the services industry and joined Aragen Bioscience. Whilst joining early in the building of the company as the director of laboratory services, he moved up through the VP level and into various C-Suite roles over nearly 11 years and led the company through the acquisition by GVK Bio.

Following a short stint as the president of ImmunoPrecise Antibodies, he most recently served as the founding CEO of Alloy Therapeutics, Inc. serving to set up the company, in-license its seminal discovery platform, and get the first customers on board.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with TJ Higley, CEO at Microsize.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with TJ, covering:

• The fast, easy, scalable, precise, and non-patent-protected benefits of micronization
• How a synergistic capability alliance led to the eventual sale of his business to Lonza Capsugel
• The risks and realities of being an entrepreneur acquiring an organization, and then the collective rewards by incentivizing a team
• How a ‘getting the band back together’ call led to TJ taking back the site he once sold to create Microsize
• The importance of strategic partnerships and recognizing that you can’t do everything yourself

TJ joined Microsize in 2022 as CEO to lead the company into the next growth phase. TJ brings 25 years of experience in the pharmaceutical market, most uniquely as a former owner and executive leader of Powdersize, Inc., the original and first CMO focused on pharmaceutical micronization in the US. TJ led both the business development efforts and oversaw the site quality team during his tenure, culminating in the acquisition of the company by Capsugel in 2015 and the integration into Lonza in 2017.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vijay Vaswani, Co-Founder & CEO at Omniscope.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vijay, covering:

• How travel expands the mind and enables you to amplify your network
• The founding story of Omniscope and its mission of using tech to help unlock the immune system
• AI can read the immune system in HD, helping with clinical trials and predictive candidate selection
• How you should be thinking about AI for drug discovery and drug development
• And what the t-shirt he wears at work says on the front...

Vijay Vaswani views technology as fundamental to humanity. He has been involved in scaling companies such as Illumina and 10X Genomics. During his leadership at Siemens Healthineers and Meridian Biosciences, he acquired and commercialized disruptive diagnostic technologies. Vijay has also participated in important IPOs in the biotechnology industry and finds his passion in improving health through the application of technology.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

See you at BPI!

M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://informaconnect.com/bioprocessinternational/?vip_code=MOLECULE30&utm_source=molecule2market&utm_medium=website

Don't miss out and we'll see you in September!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug product and sterile injectables sector with Cory Lewis CEO and President, Founder at INCOG BioPharma Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Cory, covering:

• The incredible 10-year journey of Cook Pharmica from a burning cash turnaround challenge to a $950M acquisition by Catalent.
• Customer-centric lessons learned from the franchise business model that’s being adopted by a CDMO start-up.
• The continued growth of the sterile manufacturing space in North America and several growth drivers.
• Life as a founder of a CDMO start-up after 25+ years as a senior industry exec.

Cory has spent 25 years in the CDMO space. After a spell with Baxter, he served as vice president of business development and marketing for Cook Pharmica until its 2017 sale to Catalent for $950M. He has since founded INCOG, a start-up CDMO that is investing $60M to build its 90,000 square foot headquarters in Fishers, Indiana and hiring about 150 people by the end of 2024.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dexter Tjoa, CEO at Tjoapack. With a master's from Oxford University, Dexter joined Tjoapack about 5 years ago. His career has accelerated at an incredible speed since taking over the family business from his father, who founded Tjoapack over 30 years ago in the Netherlands.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Dexter Tjoa as they speak on what it has been like to take the reins of the fast growing family business as one of the youngest CEOs in the sector. Dexter describes what the selection process has been like in trying to find a finance partner to help accelerate the company’s growth. Dexter also explains how surrounding yourself with smart people who you like and who can compliment your skills and weaknesses are essential in one’s success as a leader. Lastly, he speaks on the value of postponement packaging and how contract packaging organisations are of increasing importance, rather than an afterthought for drug developers.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sara Lesina, Global Marketing Director of Pharma & Nutrition, Capsules and Health Ingredients at Lonza. A multilingual, international marketing leader, Sara oversees the global marketing and product line management team for the capsule business of Lonza, Capsugel®.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Sara Lesina, covering how diversity in her life and career has given her a much more open, flexible and balanced view of the world and how it has helped her as a leader in a global pharma industry. Sara also explains the value of learning from failure and how making mistakes is part of the journey in stretching yourself to become a bolder and more confident individual. Lastly, Raman and Sara discuss the impact that COVID-19 has had on business and marketing efforts in the pharmaceutical and biotech space, making it clear that traditional solutions will not provide answers for the current and future challenges we face.

Please subscribe, and invite your industry colleagues to join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed.

After years of frustration with recruitment service providers in our space and seeing many of my CRO/CDMO connections miss their growth targets because their talent agenda just can’t keep up, I decided to create a talent sourcing solution for pharma & bio outsourcing. Proudly introducing, Lead Candidate.

The business has been founded purely to support ambitious, growing CROs, CDMOs and pharma service firms. Lead Candidate aims to help address many of the common issues we see guests talk about - attracting people into industry, improving diversity in our sector and simply being better prepared for growth.

For many years, I strongly believed there was a need for long-term, responsible, talent acquisition from people who genuinely understand the intricacies of our industry. And a firm that would also take responsibility for championing careers and treating people with respect. 

Whether you’re looking to build your team or find your next move, visit Lead Candidate and get in touch with the team.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rani Powers, Founder & CEO at Pluto Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rani, covering:

• Her passion for coding and what drew her into the world of biology
• How the frustration of using clunky software in the lab led to the exploration of a better alternative... and eventually her own start-up
• The value of continuous user testing in building a solution that truly works and bringing joyful experiences to biologists
• Spinning out her company from the Wyss Institute at Harvard University... in a non-conventional way
• How the adoption and implementation of AI is just getting started... and how it will evolve

Dr Rani Powers is the Founder & CEO at Pluto. She is a computational biologist, software developer, and product leader, helping biologists interface deeply with their data to make new discoveries faster.

She has expertise in deep learning, molecular biology, -omics data & product management, all focused on accelerating drug discovery with beautiful, collaborative software.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Karen Lackey, CEO at X-Chem.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Karen, covering:

• Why diversity of thought is essential in solving problems that have never been solved before
• Why did she leave the big pharma world after 30 years to join the world of academia? And how joining a global CRO enabled Karen to democratize its tech and platforms
• Why she's taking her decades of drug discovery experience to help redefine it at X-Chem
• Using AI/ML more holistically to make its innovative platform more accessible and capital-efficient to biotechs dealing with challenging small molecule projects
• Her view on biotech failures and fragmented space and the need to rethink ways to launch biotechs

Karen Lackey is the Chief Executive Officer of X-Chem, a company dedicated to delivering on the promise of a leading small molecule drug discovery partner with unmatched excellence in DNA encoded library technology, digitized drug discovery, and discovery chemistry.

Karen's over 30-year career encompasses international leadership roles within Pharma (GSK, Roche), Academia (MUSC, UA), Biotech (e.g. PyramidBio, BlinkBio, Centauri, Aurobac), Foundations/Charities (e.g. CRUK, TI Horizons) and most recently with the CRO Evotec. She is a passionate drug hunter, playing a pivotal role in discovering Tykerb, and contributing to the advancement of numerous clinical candidates and launched drugs.

Throughout her distinguished career, Karen has been at the forefront of integrated drug discovery, spanning diverse areas such as machine learning/AI/computational chemistry, medicinal chemistry, chemical biology, biochemistry, discovery biology, pharmacology, DMPK, and the application and integration of new technologies.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Fredrik Lehmann, Venture Partner at Industrifonden.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Fredrik, covering:

• How the closing of a business and customer requests led to a phoenix from the flames start-up opportunity
• His company's journey from inception and growth to eventual sale to Recipharm
• His transition to becoming a VC investor with an evergreen fund within the Nordic life science ecosystem, including the subjectivity of most investments
• The sentiment Fredrik is seeing from the biotech market and his frustrations of not being able to make more investments in breakthrough science and tech

Fredrik focuses on life science with an extra eye for innovative biotechs. He is interested in contributing to businesses with his experience in the biotech world to help companies reach their highest potential.

Fredrik has over 20 years of experience in the life science industry as CEO, Head of Research, and CMC in several companies. He has extensive experience in turning ideas into products and successful businesses and has founded six companies, including OnTarget Chemistry, which was acquired by Recipharm in 2015. He also serves as a board director at several Life Sciences companies and is a member of the Scientific Advisory Board at Akthelia Pharmaceuticals.

Fredrik holds a PhD in medicinal chemistry from Gothenburg University and an MBA from Stockholm School of Economics.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with a look back to some of our early guests from the Molecule to Market archive.

Your host, Raman Sehgal, recaps his discussions on the pharmaceutical and biotechnology supply chain with:

• Stefano Console, founder and Senior Advisor at Oriento discussing: founding his business in Switzerland and the fractional management staffing structure that is helping Oriento succeed
• Claire Thompson, founder and CEO of Agility Life Sciences discussing: her career as a footballer and how it has helped her when successfully leading a team
• Jitesh Devendra, Managing Director at Solara Active Pharma Sciences discussing:  why it is crucial to invest time internally to be just as operationally focused as you are strategically focused
• Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics discussing: her do’s and don’ts for building new business partnerships

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Will Patrick, CEO at Culture Biosciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Will, covering:

• How time at Google, MIT and Kendall Square led him to build disruptive tools and hardware for the bioprocessing sector
• Creating a cloud-based, real-time data alternative for companies wanting access to bioreactors... without the need for large-scale investment
• Why biotech and biopharma firms are embracing digitization, virtualization, and simulation... but less so at CDMOs
• Raising funds from VCs that understand the need for technological disruption
• How biotechs, biopharma companies, and CDMOs alike can leverage Culture’s proprietary, integrated, and cloud-based single-use reactor platform
• How enhanced data-driven modeling and simulation can save a lot of time and costs in upstream bioprocess development going forward

Will is an entrepreneurial engineer with a background in mechanical engineering, product design, and bioengineering. He develops hardware products at the interface of biology and digital fabrication. He holds 17 patents and has published 4 peer-reviewed journal articles. He currently runs Culture Biosciences, a company building and operating automated bioreactor infrastructure for the biotech industry.

Will graduated from the MIT Media Lab in 2015 where he was a researcher in the Mediated Matter group. His research focuses on 3D printing fluidic systems and their applications in biotechnology and product design.

Previously, he worked at Google[x] as a Rapid Evaluator where he developed and prototyped new projects for the organization. Will was a founding member of the Google[x] UAV delivery project, Project Wing, was an early team member of Project Loon, and also led the launch communications for Project Glass.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, CFO, Special Advisor & Board Member of several biotech companies, including Portage Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:

• Allan’s updated view on what is happening in the market since he was on the show last summer and his own change in investment focus
• Why a downturn, negative enterprise value, and cash burn for many biopharma and biotech firms signals an opportunity for others
• A new breed of slimmer, capital-efficient biotechs that will have a reliance on outsourcing built into their de-risk strategy
• Why the capital-intensive CGT area is not always a sure thing - investment tips from someone that has helped raised more than $4 billion in funds

Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audits and two compensation committees.

He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing; an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Carl-Åke Carlsson CEO at Xellia Pharmaceuticals. Like celebrated “one-club” football stars like Leo Messi at Barcelona, Alessandro Del Piero at Juventus and Steven Gerrard at Liverpool… Carl-Åke has been with Xellia since 1988. A pharmaceutical leader known for his class and commercial acumen, Carl‑Åke started in a finance position. He was soon diversifying into other areas and running various divisions before rising to the top as global CEO of a business that employs 1,800 people.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke Carlsson, covering Xellia’s journey from an API supplier to a global specialty pharma company known for novel anti-infective, life-saving medicines. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years, offering advice and insight from his experiences. He explains how he has created and scaled a world-class culture using internal, cross-functional “transformers” to assist in upholding values internally and externally. He speaks about the origins of the industry-renowned DCAT and CPhI Xellia parties. And lastly, he announces some exciting news about Xellia and their plans for expansion.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Erik Haeffler, VP Manufacturing Services & Head of Sustainability at Recipharm AB, Dan Stanton, Founder and Editor of Bioprocess Insider and Stefano Console, Senior Advisor and Founder at Oriento.

Join us as we discuss the impact of COVID-19 on the pharma and bio supply chain. We explore the real human challenges experienced in the face of a global pandemic and the impact these challenges have had on business. We also discuss concerns around safety and environmental impacts relating to materials suppliers.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Andi White, Head of Business Operations & Strategy for the Healthcare Industry Solutions Accelerator at Microsoft.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andi, covering:

• How five years at GE helped develop and shape Andi into a leader
• Why having a broad mindset early on in your career will help you flourish down the line
• The role of tech in revolutionizing clinical trials and drug development space
• How you should be thinking about and experimenting with AI in terms of data, convenience, and research

A clinically-savvy Ph.D. with two decades of diverse healthcare experience, Andi White has demonstrated success across all aspects of commercialization, in both start-up and Fortune 100 companies.

Andi’s corporate experience is bolstered by her years in the San Francisco start-up community, where she participated in the commercialization of several life science companies.

With a Master’s/Doctorate in Biochemistry from the University of New Hampshire and Postdoctoral research experience at UC Berkeley, Andi has a true passion for the science behind healthcare and the promise of connected data in driving the future of better patient outcomes.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

** Disclaimer **

The opinions, beliefs, and viewpoints expressed by Dr. Andrea White on this episode of the Molecule to Market podcast are solely her own and do not reflect the opinions, beliefs, and official policies of Microsoft Corporation.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeff Dill, CEO at Vynamic.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeff, covering:·    

• How to create, document, grow and internationally scale an incredible business culture.
• The shift towards greater industry collaboration as an important step for quicker drug approvals in the future.
• Servant leadership philosophy - to listen, be empathetic and enable.
• The drive and transparency needed to create a more diverse and inclusive workforce.

Jeff boasts over 20 years’ experience in the healthcare consulting world. Previously at Accenture, Jeff joined healthcare industry management consulting firm Vynamic in 2005, he has been there ever since and is now the CEO.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tamar Thompson, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering:

• The epidemiological challenge of rare diseases and representing the topic at the White House
• Why is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements?
• The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZeneca
• Some top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your champions

Tamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion’s charitable foundation and the Alexion lead for Inclusion and Diversity. 

Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors.

Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics. To say Mary has an impressive track record is an understatement. Across the last three decades she has worked for some of the biggest pharmaceutical companies in the world including Janssen and Bristol Myers Squibb before moving onto several fast growing biotech companies including Ironwood, Cyclerion and now Lyndra in senior regulatory and quality roles. She’s also a guest lecturer, a mentor to many, and a trustee for the Center for Great Expectations in New Jersey. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Mary Christian. In this episode, Mary reflects on the main differences in working with small, nimble bio and pharma companies compared to larger more structured organizations, particularly commenting on the different ways vendors are selected. She also addressed the major shift in types of relationships sponsors and vendors have with each other as she has seen things become less transactional over time. She gives valuable advice to vendors on how to get the most out of your partnership from the very beginning while explaining what a good and bad partnership experience looks like from her perspective as a sponsor. Mary gives advice based on her experience as a successful leader in the space and explains the value in having a support system at work and at home. She also highlights how important it is, for women especially, to not opt out of opportunities to further their career. Lastly Mary speaks about The Center for Great Expectations, an organization which empowers women and families battling mental health and substance disorders to break the cycle and provide better lives for their children.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jodi Cook PhD, President and CEO at Skylark Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jodi, covering:

• How a curiosity for unanswered questions led her to a PhD and a career in biotech… and, ultimately, the magical, rare experience of getting a product to market
• The full-circle moment that took Jodi from being an audiologist to becoming the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness
• The reality of running a biotech company in the most challenging climate in a long time - and why she treats every dollar in the business as if it were her own
• Dress to impress - no-nonsense advice on crafting the impression you want to leave on your audience
• Why does she allow herself to dream of what Skylark can achieve as a business and the profound impact of gene therapies on patients?

Jodi is an operationally focused business leader with experience across public and private biotechnology and medical device organizations. She brings a unique combination of scientific, clinical development, operational, and commercialization expertise to Skylark.

Before leading Skylark, Dr. Cook was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics. Before that, she served as the founding Chief Operating Officer of Agilis Biotherapeutics, overseeing its $1 billion acquisition.

She earned her Ph.D. from Arizona State University, a Master’s in Audiology from the University of South Carolina, and a Bachelor of Arts from Loyola University Maryland. She completed a fellowship at Johns Hopkins Medical School in Baltimore, Maryland. She is a Board Member of Fennec Pharmaceuticals and was previously Board Chair of STRM.BIO.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Hall, President at Lifecore Biomedical

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: 

• What a period working on the sponsor/buyer side taught him about getting best out of your CROs and CDMOs

• The challenges of doubling in size twice in just 10 years and not getting ‘too far out over your skis’
• Building a culture with longevity and not losing sight of the purpose - never hurting a patient
• Insight into market growth figures and why the injectable market remains a hot spot
• Timeless advice around not chasing the money, always be learning and keeping an open mind

Jim was appointed President in June 2017. He served as Vice President and General Manager since July 2013, Vice President of Operations since 2006 and was Director of Manufacturing Operations and Engineering since 2001; prior to that he was the Manager of Engineering and Operations at Lifecore. Mr. Hall brings over 30 years of pharmaceutical and combination product manufacturing and development experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hogan, External Manufacturing Team Lead for the Americas at Bayer Pharmaceuticals.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Daniel, covering:

• Managing a portfolio of 30-50 CMO partners across OSD, aerosols, topicals and liquids. And why due diligence and careful CMO selection is vital given its 10 x harder to exit a site.
• Some of the fundamental differences and similarities between sourcing as a big pharma and a small biotech.
• What good and bad relationships look like with an outsourced partner.
• The proliferation and availability of vendors in the outsourcing space. And why there is always room for CDMOs/CMOs with novel capabilities.
• Timeless advice for CDMOs/CMOs/CPOs in building relationships and revenue with big pharma.

With almost 20 years in the sector, Dan’s technical knowledge encompasses diverse pharmaceutical dosage forms with experience manufacturing and formulating a wide range of products for oral, topical, and parenteral administration. He thrives on contributing to complex products with the potential to cure people of disease, enabling them to lead lives of health and wellness.

Leading a team of experienced engineers responsible for the technology interface between Bayer and Contract Manufacturing Organizations (CMOs), Dan currently manages the manufacturing of a diverse dosage, multimillion-dollar product portfolio while providing guidance on activities such as process optimization, technology transfer from Bayer research and development to CMOs and validation of processes at commercial scale at various CMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with John Ross, President at Mayne Pharma US. John Ross has spent 15 years in the pharma contract services space in senior roles following some time at Eli Lilly and PWC. He joined Mayne in 2013 as a VP and transitioned to President in 2017. Today, he oversees over 550+ people in North Carolina and has managed a huge injection of investment in the business.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest John Ross, covering the contrast from working in Big Pharma versus running high-growth contract service organisations. They also discuss the increasing demand for and challenge of handling, developing and manufacturing highly potent pharmaceutical products. Lastly they trade tips for leading a senior management team in a global business while also making time to learn and balance life outside of work. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Richard Johnson, Founding Director of Upperton Pharma Solutions. With more than 25 years of experience in the industry, Richard is a founding director of two, successful pharmaceutical companies. He has authored 30 scientific publications and is the named-inventor on more than 20 patents. His research experience spans a broad range of scientific disciplines particularly in the field of pharmaceutical spray drying and drug delivery. This knowledge has been used in the successful development of a number of pharmaceutical products from early research to testing on patients.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:

• Greater collaboration and alliance between smaller, specialist early phase contract service providers as a way to compete against the global one-stop-shops.
• Increased demand for nasal and pulmonary delivery as a result oft the pandemic. And why Richard was not surprised to see a Covid-19 vaccine developed so quickly.
• The contrast of founding a steady 20-year growth business and the another that exited in just five years.
• The increasing demand and application for spray drying technology to solve modern pharmaceutical development challenges.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Martino Picardo, Chairman at Discovery Park.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Martino, covering:

• His ‘three careers’ over the last few decades, mainly spent translating science into commercial entities that make a difference.
• Building Stevenage Bioscience Catalyst from the ground-up from the middle of the golden triangle through relationships, partnerships and networking.
• The ‘holy trilogy’ of building incubators from a blank sheet to successful, thriving communities.
• Creating a life science village from a transitioning Pfizer R&D site in the UK into an ecosystem with 160 companies.
• Never being a better time to work in life sciences and for entrepreneurs to thrive in the ecosystem.

Martino is Chairman of Discovery Park and an Independent Consultant. With a a PhD in Biochemistry, Martino spent almost a decade with Amersham International after his time in academia.

He was the first CEO of the Stevenage Bioscience

Catalyst an ambitious concept to develop an Incubator and Accelerator, which is now as world class Science Park.

A former Entrepreneur in Residence at UMIP, Manchester and with the NHS, Martino is also on Board of BIONOW, and is Chairman of VisusNano Ltd and Evidential Ltd.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.